Ruxolitinib is an orally bioavailable JAK1/2 inhibitor, approved by the FDA for intermediate or high‐risk myelofibrosis and used in the setting of graft‐vs‐host disease and post‐MPN AML. This evidence concerns the gene JAK1 and acute myeloid leukemia.